Business Development

Oculis has retained commercial rights to OC-118 and its other product candidates in all territories. The company plans to commercialize them directly in key markets and/or distribute through selected pharmaceutical partnerships.

The company is also looking to enrich its pipeline with complementary products for ophthalmic diseases through in-licensing.

To discuss opportunities, please contact bd@oculis.com.